|
|
 Pharmaceutical Information - December 5, 2008
| The U.S. Food and Drug Administration is fast tracking a new drug named "arimoclomol", for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Pharmaceutical giant, CytRx, announces the initiation of a phase II clinical trial with orally-administered arimoclomol for ALS, and patient identification for this trial, which currently is underway at several clinical trial sites. Arimoclomol was granted orphan drug status designation by the FDA for the treatment of ALS in May 2005 | | The U.S. Food and Drug Administration is fast tracking a new drug named "arimoclomol", for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Pharmaceutical giant, CytRx, announces the initiation of a phase II clinical trial with orally-administered arimoclomol for ALS, and patient identification for this trial, which currently is underway at several clinical trial sites. Arimoclomol was granted orphan drug status designation by the FDA for the treatment of ALS in May 2005 | | Food and Drug Administration (FDA) Commissioner, Dr. Lester Crawford, has resigned, after repeated claims that he allowed his agency to "play politics" with drug approvals, and oversaw some very high profile drug safety recalls. The White House quickly named Andrew von Eschenbach, the director of the National Cancer Institute, as acting FDA commissioner | | Food and Drug Administration (FDA) Commissioner, Dr. Lester Crawford, has resigned, after repeated claims that he allowed his agency to "play politics" with drug approvals, and oversaw some very high profile drug safety recalls. The White House quickly named Andrew von Eschenbach, the director of the National Cancer Institute, as acting FDA commissioner | | South Korean pharmaceutical company LG Life Sciences Ltd., announces on Friday it has successfully finished the second phase of clinical trials for a hormone drug for children with growth problems LG Life Sciences also says six key medical schools in Europe have completed the two-year-long tests of the slow-release human growth hormone (SR-hGH) on approximately 50 children, who either lack growth hormones or are suffering from dwarfism | |
|
|
